Diane Hollenbaugh
Overview
Explore the profile of Diane Hollenbaugh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan S, Belmar N, Ho S, Rogers B, Stickler M, Graham M, et al.
Nat Cancer
. 2022 Mar;
3(3):337-354.
PMID: 35256819
Costimulatory receptors such as glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) play key roles in regulating the effector functions of T cells. In human clinical trials, however, GITR agonist antibodies...
2.
Ho S, Xu Z, Thakur A, Fox M, Tan S, Digiammarino E, et al.
Mol Cancer Ther
. 2020 Jan;
19(4):1040-1051.
PMID: 31974274
CD137 (TNFRSF9, 4-1BB) agonist antibodies (mAb) have demonstrated potent antitumor activity with memory response while causing hepatotoxicity in mouse models. In clinical trials, the degrees of liver toxicity of anti-CD137...
3.
Ye S, Cohen D, Belmar N, Choi D, Tan S, Sho M, et al.
Cancer Immunol Res
. 2019 Aug;
7(11):1864-1875.
PMID: 31462409
Agonistic CD40 monoclonal antibodies (mAb) have demonstrated some clinical activity, but with dose-limiting toxicity. To reduce systemic toxicity, we developed a bispecific molecule that was maximally active in the presence...
4.
Purcell J, Tanlimco S, Hickson J, Fox M, Sho M, Durkin L, et al.
Cancer Res
. 2018 May;
78(14):4059-4072.
PMID: 29764866
Progress in understanding tumor stromal biology has been constrained in part because cancer-associated fibroblasts (CAF) are a heterogeneous population with limited cell-type-specific protein markers. Using RNA expression profiling, we identified...
5.
Belmar N, Chan S, Fox M, Samayoa J, Stickler M, Tran N, et al.
J Immunol
. 2017 Apr;
198(11):4502-4512.
PMID: 28446565
Recent advances in immuno-oncology have shown that the immune system can be activated to induce long-term, durable antitumor responses. For immuno-oncology drug development, immune activation is often explored using rat...
6.
Harding T, Long L, Palencia S, Zhang H, Sadra A, Hestir K, et al.
Sci Transl Med
. 2013 Mar;
5(178):178ra39.
PMID: 23536011
The fibroblast growth factor (FGF) pathway promotes tumor growth and angiogenesis in many solid tumors. Although there has long been interest in FGF pathway inhibitors, development has been complicated: An...
7.
Larsen C, Elwood E, Alexander D, Ritchie S, Hendrix R, Tucker-Burden C, et al.
J Immunol
. 2011 Feb;
186(5):2693-7.
PMID: 21325218
No abstract available.
8.
Gilson C, Milas Z, Gangappa S, Hollenbaugh D, Pearson T, Ford M, et al.
J Immunol
. 2009 Jul;
183(3):1625-35.
PMID: 19592649
Blockade of the CD40/CD154 signaling pathway using anti-CD154 Abs has shown promise in attenuating the alloimmune response and promoting long-term graft survival in murine model systems, although side effects observed...
9.
Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, et al.
Science
. 2008 May;
320(5877):807-11.
PMID: 18467591
To understand the system of secreted proteins and receptors involved in cell-cell signaling, we produced a comprehensive set of recombinant secreted proteins and the extracellular domains of transmembrane proteins, which...
10.
Hollenbaugh D, Aruffo A
Curr Protoc Immunol
. 2008 Apr;
Chapter 10:Unit 10.19A.
PMID: 18432866
Recombinant DNA technology has allowed the preparation of chimeric genes encoding proteins with novel properties. This unit describes the construction and subsequent testing of genes encoding immunoglobulin chimeras. The first...